B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection

Nature Communications

Volumn 1, Issue 7, 2010, Pages

  Huang, Kuan Hsiang G ^a   Bonsall, David ^b   Katzourakis, Aris ^c   Thomson, Emma C ^b   Fidler, Sarah J ^b   Main, Janice ^b   Muir, David ^b   Weber, Jonathan N ^b   Frater, Alexander J ^a   Phillips, Rodney E ^a   Pybus, Oliver G ^c   Goulder, Philip J R ^a   McClure, Myra O ^b   Cooke, Graham S ^b   Klenerman, Paul ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS NEUTRALIZING ANTIBODY; CD20 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG; GAMMA INTERFERON; MONOCLONAL ANTIBODY;

ADULT; ANAMNESIS; ANTIBODY PRODUCTION; ARTICLE; B CELL DEPLETION; B LYMPHOCYTE; CANCER GRADING; CASE REPORT; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL SELECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IMMUNOTHERAPY; LYMPHOMA; LYMPHOPLASMACYTOID LYMPHOMA; MALE; SEQUENCE ANALYSIS; VIRUS LOAD; BIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; SITE DIRECTED MUTAGENESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMPUTATIONAL BIOLOGY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED;

EID: 84879107855     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1100     Document Type: Article

References (59)

1. Goulder, P.J. &Watkins, D.I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8, 619-30 (2008).
2. Schmitz, J.E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857-860 (1999).
3. Hersperger, A.R. et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 6, e1000917 (2010).
4. McMichael, A. &Hanke, T. The quest for an AIDS vaccine: Is the CD8+ T-cell approach feasible? Nat. Rev. Immunol. 2, 283-291 (2002). (Pubitemid 37323228)
5. Buchbinder, S.P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
6. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.N. Engl.J. Med. 361, 2209-2220 (2009).
7. Sattentau, Q. Correlates of antibody-mediated protection against HIV infection. Curr. Opin. Immunol. 3, 368-374 (2008). (Pubitemid 351521023)
8. Scheid, J.F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
9. Moir, S. &Fauci, A.S. B cells in HIV infection and disease. Nat. Rev. Immunol. 9, 235-245 (2009).
10. Pantophlet, R. &Burton, D.R. GP120: Target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24, 739-769 (2006).
11. Phillips, R.E. et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453-459 (1991). (Pubitemid 21896855)
12. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003). (Pubitemid 36378357)
13. Frost, S.D. et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl Acad. Sci. USA 102, 18514-18519 (2005). (Pubitemid 43011257)
14. Richman, D.D., Wrin, T., Little, S.J. &Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144-4149 (2003). (Pubitemid 36418171)
15. Mahalanabis, M. et al. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.J. Virol. 83, 662-672 (2009).
16. Burton, D.R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994). (Pubitemid 24373715)
17. Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10, 359-369 (1994). (Pubitemid 24141210)
18. Walker, L.M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
19. Stiegler, G. et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17, 1757-1765 (2001). (Pubitemid 34114213)
20. Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732-737 (2007). (Pubitemid 46279718)
21. Braibant, M. et al. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: Prevalence and association with neutralizing activity. AIDS 20, 1923-1930 (2006). (Pubitemid 44427609)
22. Simek, M.D. et al. Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.J. Virol. 83, 7337-7348 (2009).
23. Virgin, H.W. &Walker, B.D. Immunology and the elusive AIDS vaccine. Nature 464, 224-231.
24. Mease, P.J. B cell-targeted therapy in autoimmune disease: Rationale, mechanisms, and clinical application.J. Rheumatol. 35, 1245 (2008).
25. Lim, F. &Abdalla, S.H. Interactions between HIV infection and lymphoplasmacytoid lymphoma. Leuk. Lymphoma 47, 163-166 (2006). (Pubitemid 43101742)
26. Fidler, S. et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 16, 2049-2054 (2002). (Pubitemid 35205269)
27. Drummond, A.J. &Rambaut, A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol. Biol. 7, 214 (2007).
28. Kwong, P.D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998). (Pubitemid 28289647)
29. Wu, X. et al. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.J. Virol. 83, 10892-10907 (2009).
30. Zhang, M.Y. et al. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.J. Virol. 78, 9233-9242 (2004).
31. Duenas-Decamp, M.J., Peters, P.J., Burton, D. &Clapham, P.R. Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes.J. Virol. 83, 2575-2583 (2009).
32. Scanlan, C.N. et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120.J. Virol. 76, 7306-7321 (2002).
33. Liossis, S.N. &Sfikakis, P.P. Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells. Clin. Immunol. 127, 280-285 (2008).
34. Garcia-Rodriguez, M.J., Canales, M.A., Hernandez-Maraver, D. &Hernandez-Navarro, F. Late reactivation of resolved hepatitis B virus infection: An increasing complication post rituximab-based regimens treatment? Am.J. Hematol. 83, 673-675 (2008).
35. Schmitz, J.E. et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus.J. Virol. 77, 2165-2173 (2003). (Pubitemid 36110029)
36. Miller, C.J. et al. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.J. Virol. 81, 5024-5035 (2007). (Pubitemid 46744414)
37. Gaufin, T. et al. Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host.J. Virol. 83, 10347-10357 (2009).
38. Aksoy, S. et al. Rituximab-related viral infections in lymphoma patients. Leuk. Lymphoma 48, 1307-1312 (2007). (Pubitemid 47079357)
39. Maini, M.K. et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 117, 1386-1396 (1999).
40. Sinicco, A. et al. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: No evidence of faster progression to AIDS. Scand.J. Infect. Dis. 29, 111-115 (1997).
41. Rockstroh, J.K. Influence of viral hepatitis on HIV infection.J. Hepatol. 44, S25-27 (2006). (Pubitemid 43053869)
42. Burton, D.R., Stanfield, R.L. &Wilson, I.A. Antibody versus HIV in a clash of evolutionary titans. Proc. Natl Acad. Sci. USA 102, 14943-14948 (2005). (Pubitemid 41513316)
43. Bailey, J.R. et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.J. Virol. 80, 4758-4770 (2006).
44. Harrer, T. et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res. Hum. Retroviruses 12, 585-592 (1996). (Pubitemid 26120291)
45. Hessell, A.J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007). (Pubitemid 47373775)
46. Hessell, A.J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951-954 (2009).
47. Xiao, P. et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.J. Virol. 84, 7161-7173.
48. Mascola, J.R. &Montefiori, D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28, 413-444.
49. Lewis, G.K. Challenges of antibody-mediated protection against HIV-1. Expert Rev. Vaccines 9, 683-687.
50. Ahuja, A., Anderson, S.M., Khalil, A. &Shlomchik, M.J. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA 105, 4802-4807 (2008). (Pubitemid 351753827)
51. Derdeyn, C.A. et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303, 2019-2022 (2004). (Pubitemid 38393277)
52. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.J. Virol. 79, 10108-10125 (2005). (Pubitemid 41098552)
53. Dorfman, T., Popova, E., Pizzato, M. &Gottlinger, H.G. Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix.J. Virol. 76, 6857-6862 (2002). (Pubitemid 34633554)
54. Martin, L. et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 21, 71-76 (2003). (Pubitemid 36055830)
55. Frater, A.J. et al. Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression.J. Virol. 81, 6742-6751 (2007). (Pubitemid 46878078)
56. Shankarappa, R. et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.J. Virol. 73, 10489-10502 (1999).
57. Yang, Z. &Nielsen, R. Synonymous and nonsynonymous rate variation in nuclear genes of mammals.J. Mol. Evol. 46, 409-418 (1998). (Pubitemid 28164945)
58. Drummond, A.J., Ho, S.Y., Phillips, M.J. &Rambaut, A. Relaxed phylogenetics and dating with confidence. PLoS Biol. 4, e88 (2006).
59. Drummond, A.J., Rambaut, A., Shapiro, B. &Pybus, O.G. Bayesian coalescent inference of past population dynamics from molecular sequences. Mol. Biol. Evol. 22, 1185-1192 (2005). (Pubitemid 40577756)